Initial Insights into Targeted Axillary Dissection Post-Neoadjuvant Therapy in Node-Positive Breast Cancer: A Pilot Interventional Study.

Q2 Medicine
A Aosmali, M Nafie, A Nafie, R Radwan, B Soliman, M Alkhalaf
{"title":"Initial Insights into Targeted Axillary Dissection Post-Neoadjuvant Therapy in Node-Positive Breast Cancer: A Pilot Interventional Study.","authors":"A Aosmali, M Nafie, A Nafie, R Radwan, B Soliman, M Alkhalaf","doi":"10.7417/CT.2025.5252","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The most commonly detected malignancy and the second most prevalent cause of cancer-related death in women globally is breast cancer. The treatment of breast cancer is significantly influen-ced by the accurate staging and proper management of axillary lymph nodes (ALNs). The surgical management of the axilla in breast cancer has undergone a significant transformation over the past two decades. The routine axillary lymph nodes (LN) dissection, which is associated with a higher level of morbidity in early-stage node-negative patients, has been replaced by sentinel LN biopsy (SLNB), which was initially investigated in the early nineties. SLNB offers precise evaluations of nodal status and essential staging data.</p><p><strong>Objective: </strong>To determine the accuracy of targeted axillary resection and ensuring surgical removal of clipped nodes would improve accuracy of nodal staging in those patients.</p><p><strong>Patients and methods: </strong>This Pilot Interventional study was conducted at Al Demerdash Hospital, Faculty of Medicine, Ain Shams University, between March 2020 and March 2021. The institutional research and ethics committee reviewed and approved the study protocol. Thirty patients with clinical node-positive breast cancer who were undergoing neo-adjuvant chemotherapy (NACT) were involved in the study.</p><p><strong>Results: </strong>In all, 24 patients with clipped ALNs were stained with patent blue dye and five patients with clipped ALNs were not stained by patent blue dye. Therefore, SLNB was unable to detect five clipped ALNs in five patients, so there is a false-negative rate (FNR) of 17.2%. Therefore, with the targeted procedure we can decrease the FNR of sentinel nodes.</p><p><strong>Conclusion: </strong>Targeted axillary dissection is a feasible technique for axillary management in clinically N1 breast cancer patients who receive NACT and turned to N0. Preoperative clipped node guide wire localization significantly enhances the identification clipped node rate and decreases the FNR of SLNB alone.</p>","PeriodicalId":50686,"journal":{"name":"Clinica Terapeutica","volume":"176 4","pages":"487-494"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Terapeutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7417/CT.2025.5252","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The most commonly detected malignancy and the second most prevalent cause of cancer-related death in women globally is breast cancer. The treatment of breast cancer is significantly influen-ced by the accurate staging and proper management of axillary lymph nodes (ALNs). The surgical management of the axilla in breast cancer has undergone a significant transformation over the past two decades. The routine axillary lymph nodes (LN) dissection, which is associated with a higher level of morbidity in early-stage node-negative patients, has been replaced by sentinel LN biopsy (SLNB), which was initially investigated in the early nineties. SLNB offers precise evaluations of nodal status and essential staging data.

Objective: To determine the accuracy of targeted axillary resection and ensuring surgical removal of clipped nodes would improve accuracy of nodal staging in those patients.

Patients and methods: This Pilot Interventional study was conducted at Al Demerdash Hospital, Faculty of Medicine, Ain Shams University, between March 2020 and March 2021. The institutional research and ethics committee reviewed and approved the study protocol. Thirty patients with clinical node-positive breast cancer who were undergoing neo-adjuvant chemotherapy (NACT) were involved in the study.

Results: In all, 24 patients with clipped ALNs were stained with patent blue dye and five patients with clipped ALNs were not stained by patent blue dye. Therefore, SLNB was unable to detect five clipped ALNs in five patients, so there is a false-negative rate (FNR) of 17.2%. Therefore, with the targeted procedure we can decrease the FNR of sentinel nodes.

Conclusion: Targeted axillary dissection is a feasible technique for axillary management in clinically N1 breast cancer patients who receive NACT and turned to N0. Preoperative clipped node guide wire localization significantly enhances the identification clipped node rate and decreases the FNR of SLNB alone.

淋巴结阳性乳腺癌新辅助治疗后靶向腋窝清扫的初步见解:一项初步介入研究。
背景:在全球范围内,乳腺癌是最常见的恶性肿瘤,也是导致女性癌症相关死亡的第二大常见原因。腋窝淋巴结的准确分期和适当处理对乳腺癌的治疗有重要影响。在过去的二十年里,乳腺癌腋窝的手术治疗经历了重大的转变。常规腋窝淋巴结清扫术(LN)在早期淋巴结阴性患者中具有较高的发病率,已被前哨淋巴结活检(SLNB)所取代,该方法最初于90年代初进行研究。SLNB提供精确的节点状态评估和基本分期数据。目的:探讨腋窝靶向切除的准确性,确保手术切除夹住的淋巴结可提高淋巴结分期的准确性。患者和方法:本介入试验研究于2020年3月至2021年3月在艾因沙姆斯大学医学院Al Demerdash医院进行。机构研究和伦理委员会审查并批准了研究方案。30例临床淋巴结阳性乳腺癌患者正在接受新辅助化疗(NACT)。结果:24例aln夹持染色成功,5例aln夹持未染色。因此,SLNB无法检测到5例患者的5个aln,因此假阴性率(FNR)为17.2%。因此,有针对性的手术可以降低前哨淋巴结的FNR。结论:靶向腋窝清扫是临床N1型乳腺癌患者行NACT转N0型治疗的可行方法。术前夹淋巴结导丝定位可显著提高识别夹淋巴结率,降低单行SLNB的FNR。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinica Terapeutica
Clinica Terapeutica PHARMACOLOGY & PHARMACY-
CiteScore
2.50
自引率
0.00%
发文量
124
审稿时长
6-12 weeks
期刊介绍: La Clinica Terapeutica è una rivista di Clinica e Terapia in Medicina e Chirurgia, fondata nel 1951 dal Prof. Mariano Messini (1901-1980), Direttore dell''Istituto di Idrologia Medica dell''Università di Roma “La Sapienza”. La rivista è pubblicata come “periodico bimestrale” dalla Società Editrice Universo, casa editrice fondata nel 1945 dal Comm. Luigi Pellino. La Clinica Terapeutica è indicizzata su MEDLINE, INDEX MEDICUS, EMBASE/Excerpta Medica.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信